Leukotrienes antagonists in the management of bronchial asthma.
Leukotrienes antagonists represent the first new class of anti-asthma drugs available in the last two decennia, based on the great progress from medical research to clinical practice. They have been already intensively studied in many clinical trials and continue to be an important subject of debate. This article intends to summarize the most recent data published in the literature about the role of leukotrienes in the pathogenesis of asthma and the actions of leukotrienes antagonists, pointing out their benefits in the light of the concept of efficacy and effectiveness.